DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice

Completed

Conditions: HCV Infection

Interventions: Drug: Sovaldi

First Posted Date: 2016-05-26

Last Posted Date: 2018-10-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 25

Registration Number: NCT02783976

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Fatty Liver Disease (NAFLD)

Interventions: Drug: SEL
Drug: FIR
Drug: CILO
Drug: FENO
Drug: VAS

First Posted Date: 2016-05-24

Last Posted Date: 2022-03-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 220

Registration Number: NCT02781584

Locations: 🇺🇸
Pinnacle Clinical Research, PLLC, San Antonio, Texas, United States
🇺🇸
American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States
🇺🇸
Gastro One, Germantown, Tennessee, United States

and more 9 locations

Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL

First Posted Date: 2016-05-24

Last Posted Date: 2018-11-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 79

Registration Number: NCT02781571

Locations: 🇪🇸
Hospital Ramón Y Cajal, Madrid, Spain
🇪🇸
La Fe Hospital, Valencia, Spain
🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain

and more 12 locations

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL
Drug: RBV

First Posted Date: 2016-05-24

Last Posted Date: 2018-11-27

Lead Sponsor: Gilead Sciences

Target Recruit Count: 204

Registration Number: NCT02781558

Locations: 🇪🇸
Hospital Universitario Donostia, San Sebastian, Spain
🇪🇸
Hospital Universitario Virgen De La Arrixaca, Murcia, Spain
🇪🇸
Complexo Hospitalario Universitario de Montecelo, Pontevedra, Spain

and more 24 locations

Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis

Phase 2

Terminated

Conditions: Cystic Fibrosis

Interventions: Drug: Andecaliximab
Drug: Placebo

First Posted Date: 2016-05-03

Last Posted Date: 2018-08-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 6

Registration Number: NCT02759562

Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

Phase 4

Terminated

Conditions: Lymphoid Malignancies

Interventions: Drug: Idelalisib

First Posted Date: 2016-04-15

Last Posted Date: 2020-03-04

Lead Sponsor: Gilead Sciences

Target Recruit Count: 3

Registration Number: NCT02739360

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: LDV/SOF
Drug: SOF
Drug: RBV

First Posted Date: 2016-04-14

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 239

Registration Number: NCT02738333

Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL

First Posted Date: 2016-04-05

Last Posted Date: 2019-02-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 9

Registration Number: NCT02728206

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL

First Posted Date: 2016-03-30

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 119

Registration Number: NCT02722837

Locations: 🇷🇺
Central Research Institute of Epidemiology, Moscow, Russian Federation
🇷🇺
First Moscow State Medical University I.M. Sechenov, Moscow, Russian Federation
🇷🇺
Limited Liability Company "Clinic Tour", Moscow, Russian Federation

and more 12 locations

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

Phase 3

Completed

Conditions: HCV Infection
HIV-1 Infection

Interventions: Drug: E/C/F/TAF
Drug: F/R/TAF
Drug: LDV/SOF

First Posted Date: 2016-03-14

Last Posted Date: 2018-11-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 150

Registration Number: NCT02707601

Locations: 🇺🇸
Be Well Medical Center, Berkley, Michigan, United States
🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 39 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy